Eloxx Pharmaceuticals announced that the first patients have now been dosed in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. Topline results are expected in the first half of 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELOX:
- Eloxx announces first patients enrolled in Phase 2 study of ELX-02
- Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
- Biotech Alert: Searches spiking for these stocks today
- Eloxx Pharmaceuticals price target lowered to $50 from $120 at Oppenheimer
